期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

分子靶向抗肿瘤药物十年历程启迪 被引量：3

Molecular targeted anti-tumor drugs development in past decade
原文传递
导出
摘要 本文综合分析近十年来分子靶向抗肿瘤药物的历程,回顾各类分子靶向抗肿瘤药物的特点,提出分子靶向抗肿瘤药物开发中值得关注的几个问题:如药物的毒副作用、耐受性,个体化治疗与生物标志物,以及预测敏感患者生物标志物研究等。 Several issues of molecular targeted anti-tumor drugs, such as drug adverse reactions, tolerance, individual therapy, as well as sensitive biomarkers are concerned. This review analyses the development in molecular targeted anti-tumor drugs in past decade.
作者 丁健
机构地区 中国科学院上海药物研究所
出处 《世界临床药物》 CAS 2012年第1期40-44,共5页 World Clinical Drug
关键词 分子靶向抗肿瘤药物 药物开发 个体化治疗 生物标志物 molecular targeted anti-tumor drug drug development individual treatment biomarker
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献27

  • 1Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents [J]. Nat Rev Cancer, 2010, 10 (4) : 241-253.
  • 2Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC [J]. Science, 2002, 297 (5578) : 102-104.
  • 3Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage[J]. Nat Rev Mol Cell Bio, 2004, 5 (11): 875-885.
  • 4Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma [J]. N Eng J Med, 2010, 363 (4) : 809-819.
  • 5Solit D, Sawyers CL. Drug discovery: How melanomas bypass new therapy [J]. Nature, 2010, 468 (7326) : 902-903.
  • 6Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation[J]. Nature, 2010, 468 (7326) : 968-972.
  • 7Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation [J]. Nature, 2010,468 (7326) : 973-977.
  • 8McDermott U, Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology [J]. J Clin Oncol, 2009, 27 (33) : 5650-5659.
  • 9Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J]. Science, 2007, 316 (5827): 1039-1043.
  • 10Kummar S, Chen HX, Wright J, et al. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements [J]. Nat Rev Drug Discov, 2010, 9(11): 843-856.

同被引文献60

  • 1邓宏伟,郭妍,孙烨,徐宇虹.靶向表皮生长因子受体的全新小分子配体筛选[J].生物化学与生物物理进展,2005,32(2):180-186. 被引量：8
  • 2韩洁,翁新楚,毕开顺.紫草中活性成分的体外抗癌作用[J].精细化工,2007,24(5):473-476. 被引量：13
  • 3卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团重庆出版社,2009:700-701.
  • 4Liauw WS.Molecular mechanisms and clinical use of tar- geted anticancer drugs [J].Aust Prescriber, 2013,36 (4) : 126-131.
  • 5Salles G, Seymour JF, Ofther F, et al.Rituximab mainte- nance for 2 years in patients with high tumour burden fol- licular lymphoma responding to rituximab plus chemo- therapy (PRIMA) .a phase 3, randomised controlled trial [ J ] .Lancet, 2011,377 (9759) : 42-51.
  • 6Baselga J, Bradbury I, Eidtmann H, et al.Lapatinib with trastuzumab for HER2-positive early breast cancer (Neo- ALTTO) : a randomised, open-label, multicentre, phase 3 trial[J].Lancet, 2012,379(9816) : 633-640.
  • 7Zhou C, Wu YL, Chen G, et al.Erlotinib versus chemo- therapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OP- TIMAL, CTONG-0802) : a multicentre, open-label,randomised, phase 3 study [J].Lancet Oncol, 2011, 12 (8) :735-742.
  • 8Rosell R, Carcereny E, Gervais R, et al.Erlotinib versus standard chemotherapy as first-line treatment for Europe- an patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC) : a multicentre, open-label, randomised phase 3 trial [J]. Lancet Oncol, 2012,13(3) :239-246.
  • 9Rosell R, Moran T, Queralt C, et al.Screening for epider- mal growth factor receptor mutations in lung cancer [J]. N Engl J Med, 2009,361 (10) : 958-967.
  • 10Van Cutsem E, Kang Y, Chung H, et al.Efficacy results from the ToGA trial : a phase Ⅲ study of trastuzumab add- ed to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive ad- vanced gastric cancer (GC) [J]. J Clin Oncol, 2009, 27 (lgs) :LBA4 509.

引证文献3

二级引证文献6

世界临床药物
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部